New York, June 5, 2026, 16:04 (ET)
NeOnc Technologies Holdings Inc. was last up 6.7% at $4.87 in late trading Friday. The brain-cancer drug developer’s shares added 30.5 cents, after hitting a range between $4.64 and $4.90 on about 33,500 shares traded. The Nasdaq name now carries a market cap of roughly $113 million.
Why it matters now: NeOnc’s next catalysts are clinical trial results and regulatory updates rather than earnings. On May 18, the company said NEO212 finished Phase 1 dose escalation and set the Phase 2 dose at 610 mg. Interim data from the fully enrolled Phase 2a trial for NEO100 in recurrent IDH1-mutant high-grade glioma are due around August. CEO Amir Heshmatpour said the quarter was “a transformational period.” GlobeNewswire
NeOnc is a clinical-stage biopharma company. Its drugs are still in testing and none are approved for sale. NeOnc works on cancers in the central nervous system, like the brain and spinal cord, and claims its platform aims to get past the blood-brain barrier. That is the filter that often keeps medicines out of the brain.
Insider buying has put the stock in focus. NeOnc said May 5 that Heshmatpour bought over $500,000 of shares in the past few weeks, and close to $1 million in the last year, all with his own money. He called this a “defining phase” for the company. GlobeNewswire
More analysts are covering the stock. BTIG, Alliance Global Partners, and Maxim Group have all put out recent Buy-rated calls, according to Benzinga’s analyst page, setting price targets at $13, $15, and $20. Consensus sits at $16. The price target is just an estimate by analysts, not the actual market price or a guarantee.
Wall Street fell Friday after a stronger May jobs report, Reuters said, which weighed on hopes for lower Fed rates. Peter Cardillo, chief market economist at Spartan Capital Securities, said the data gave “another reason” for the Fed to consider a hike. The SPDR S&P Biotech ETF dropped 3.5%. The iShares Nasdaq Biotechnology ETF slid 1.7%. Reuters
NeOnc went a different direction than some other CNS-cancer names. Plus Therapeutics, running its REYOBIQ program in brain and CNS cancers like recurrent glioblastoma, dropped 8.3%. Kazia Therapeutics, with paxalisib for glioblastoma, slipped 3.5%. Small clinical-stage oncology players often trade off their own news, even when the sector is soft.
NeOnc is still a financing story, not just a science one. In its latest quarterly filing, the company reported $138,601 in cash as of March 31 and an $8.82 million net loss for the quarter, bringing its accumulated deficit to $121.6 million. NeOnc said these numbers raise “substantial doubt” about its ability to keep operating over the next year—a standard accounting warning. If it can’t raise more cash, NeOnc said it might have to cut back or even shut down. Weak trial results or another dilutive raise could also hit the stock. NeOnc
NEO100 holders now look to see if Friday’s bounce will stick before they get NEO100 data or fresh word on how FDA talks for NEO212 are going. With a company this size, shares can trade ahead of headlines.
